home / stock / aqst / aqst news

AQST News and Press, Aquestive Therapeutics Inc. From 11/17/21

Stock Information
Company Name: Aquestive Therapeutics Inc.
Stock Symbol: AQST
Market: NASDAQ
Website: aquestive.com
Menu
AQST AQST Quote AQST Short AQST News AQST Articles AQST Message Board
Get AQST Alerts

News, Short Squeeze, Breakout and More Instantly...
AQST - Aquestive Therapeutics to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference

WARREN, N.J., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the manageme...
AQST - Aquestive Therapeutics, Inc. (AQST) Q3 2021 Earnings Call Transcript

Image source: The Motley Fool. Aquestive Therapeutics, Inc. (NASDAQ: AQST) Q3 2021 Earnings Call Nov 03, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Aquestive Therapeutics, Inc. (AQST) Q3 2021 Earnings Call Tran...

AQST - Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q3 2021 Results - Earnings Call Transcript

Aquestive Therapeutics, Inc. (AQST) Q3 2021 Earnings Conference Call November 3, 2021 08:00 AM ET Company Participants Bennett Watson - IR Keith Kendall - President & CEO Ernie Toth - CFO Dan Barber - COO Conference Call Participants Evan Hua - BMO Capital Markets Jason Butler - JMP Secur...

AQST - Aquestive Therapeutics EPS beats by $0.06, beats on revenue

Aquestive Therapeutics (NASDAQ:AQST): Q3 GAAP EPS of -$0.37 beats by $0.06. Revenue of $13.28M (+60.0% Y/Y) beats by $2.27M. Press Release For further details see: Aquestive Therapeutics EPS beats by $0.06, beats on revenue

AQST - Aquestive Therapeutics Reports Third Quarter 2021 Financial Results, Provides Business Update and Improves Full Year Guidance

Libervant™ (diazepam) Buccal Film continues to progress through the FDA review process in advance of PDUFA goal date of December 23, 2021 AQST-109 top line Phase 1 trial demonstrates clinical results comparable to autoinjectors (such as EpiPen® and Auvi-Q®) for the em...

AQST - Notable earnings after Tuesday's close

ADC, AFG, DADA, AIZ, AKAM, AMCR, AMED, AMGN, ANDE, APPS, AQST, ATVI, AWK, AYX, BFAM, BGFV, BKH, BTG, BXC, CASA, CDK, CDLX, CERS, CGBD, CHCT, CHK, CLW, COUR, CRK, [CSLT]], CVGI, CZR, DCP, DCPH, DENN, DHT, DOX, DRRX, [DVN]], EARN, EGHT, EIX, EKSO, ELVT, ENLC, EXAS, EXEL, FMC, FNF, FRG, GAIN, GN...

AQST - Aquestive Therapeutics Reports Positive Topline Data from Phase 1 Pharmacokinetic Trial of AQST-109 (epinephrine prodrug sublingual film) Supporting its Development as an Oral Alternative to Epinephrine Autoinjectors for the Emergency Treatment of Allergi

First and only orally delivered epinephrine product candidate AQST-109 demonstrates clinical results comparable to autoinjectors (such as EpiPen® and Auvi-Q®) for the emergency treatment of allergic reactions Median time to peak concentration (T max ) of ...
AQST - Aquestive Therapeutics to Report Third Quarter 2021 Financial Results and Recent Business Highlights on November 2 and Host Conference Call on November 3 at 8:00 a.m. ET

WARREN, N.J., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it will repo...

AQST - Aquestive Therapeutics Reaches Agreement to Extend Principal Payments Due Under Credit Facility to March 30, 2023 and Receives Bridge Waiver of Principal Debt Payment in Advance of Concluding Formal Agreement

WARREN, N.J., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it has reach...

AQST - IntelGenx and Aquestive Therapeutics Partner with Leading Men's Health Company to Market Tadalafil Oral Films in the U.S.

SAINT LAURENT, Quebec, Sept. 29, 2021 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSXV:IGX) (OTCQB:IGXT) (“IntelGenx”) today announced that its co-development and commercialization partner for Tadalafil oral films for the treatment of erectile dysfunction (“ED”) and ben...
Previous 10 Next 10